Microbiome / FMT

Based on the provided sources, advanced 'omic' technologies have revealed the human gut microbiota to function comparably to a newly discovered organ, significantly influencing host health, metabolic diseases, cardiovascular conditions like hypertension, type 2 diabetes, and gut-brain interactions [2, 3, 4, 8]. Environmental factors and diet strongly modulate this microbial community [6], prompting clinical and dietary interventions—such as probiotics, prebiotics, and specific colon bacteria stimulation—to target disturbed microbiota in conditions ranging from neonatal care in very low birth weight infants to adult health [1, 5, 10].

Despite substantial progress, open questions remain. Reports frequently vary regarding the precise association of specific bacterial taxonomic groups with diseases such as type 2 diabetes [4], and the exact mechanistic participation of gut microbiota dysbiosis in the development of conditions like hypertension has largely remained unknown [3]. Additionally, while preclinical rodent models strongly implicate the microbiota in gut-brain communication [8], translating these findings robustly to human clinical medicine requires further study.